obesity drugs

Pfizer Stock (PFE) News Today: Dividend, 2026 Guidance Call, Obesity Deals, and Analyst Forecasts (Dec. 15, 2025)

Pfizer Inc. (NYSE: PFE) enters the new week with its stock hovering around $25.85 in early Monday trading, as investors weigh a familiar late-2025 mix: a high dividend, a rebuilding growth story after the COVID boom, and a pipeline/M&A strategy

15 December 2025

Pfizer (PFE) Stock Outlook After the November 21 FDA Win: Obesity Deals, Cost Cuts and a 6.7% Dividend Yield

As of December 11, 2025, Pfizer Inc. (NYSE: PFE) is trying to rewrite its post‑COVID story. The stock trades around $25.66 per share, after a choppy year of guidance upgrades, obesity-drug M&A, aggressive cost cuts and fresh regulatory wins in

11 December 2025

Dividend Stocks · FDA Approvals · Investment News · NYSE:PFE · Pharmaceutical Industry · Stock Analysis

Pfizer (PFE) Stock Today: Price, Metsera Obesity Deal, 2025–2026 Forecast and Key Risks

Pfizer, Inc. (NYSE: PFE) is back in focus on December 5, 2025, as investors weigh a near‑7% dividend yield, fresh analyst commentary, a major obesity‑drug acquisition and a slate of upcoming guidance that will shape expectations for 2026. Below is

5 December 2025

Financial Forecasts · Investment Strategies · NYSE:PFE · Obesity Treatment · Pfizer News · Stock Market

Eli Lilly (LLY) Stock Outlook: Can the Obesity-Drug Giant Keep Justifying a $1,000 Share Price?

Updated: December 5, 2025 Eli Lilly and Company (NYSE: LLY) remains one of the most closely watched stocks in global markets as investors weigh eye‑popping growth in obesity and diabetes drugs against equally eye‑popping valuations and rising political pressure on

5 December 2025

Company Analysis · Financial News · Investing · Pharmaceuticals · Stock Market

Amgen (AMGN) Stock Near Record Highs on Obesity Drug Hopes – Is It Still a Buy in December 2025?

Updated: December 4, 2025 Amgen Inc. (NASDAQ: AMGN) has quietly turned into one of 2025’s standout large‑cap healthcare winners. The biotech heavyweight is trading just below fresh 52‑week highs, powered by a clean sweep of earnings beats, a deepening obesity‑drug

4 December 2025

Biotech · Financial Analysis · Investing · NASDAQ:AMGN · Pharmaceuticals · Stock Market

Amgen (AMGN) Stock Hits New 52‑Week High as Obesity Drug Bets and Analyst Upgrades Fuel 2025 Rally

Published: December 3, 2025 Amgen Inc. (NASDAQ: AMGN) is closing out 2025 on a powerful upswing. As of the close on December 3, 2025, Amgen shares finished at $345.42, up about 2% on the day, and nudged higher in after-hours

3 December 2025

Health Care Industry · Investment Strategies · Market Analysis · NASDAQ:AMGN · Pharmaceuticals · Stock Market

Pfizer Stock (PFE) Today – Price, Metsera Obesity Bet, RSV Vaccine Tailwinds and 2026 Forecast (3 December 2025)

Pfizer Inc. (NYSE: PFE) remains one of the most closely watched healthcare stocks as of December 3, 2025. The share price is still stuck near post‑COVID lows, but a new $10 billion obesity‑drug acquisition, expanding RSV vaccine markets and a

3 December 2025

Financial Forecasts · Investment Strategies · NYSE:PFE · Pfizer Analysis · Pharmaceuticals · Stock Market

Amgen Stock (AMGN) Today: Q3 2025 Earnings Beat, MariTide Obesity Drug Outlook and 2030 Price Forecast

Updated December 1, 2025 Amgen stock at a glance on December 1, 2025 Amgen Inc. (NASDAQ: AMGN) closed today at $337.49, down about 2.3% on the session, according to real‑time quote data. StockAnalysis Despite today’s pullback, the stock has had

1 December 2025

Biotech News · Earnings Reports · Investment Strategies · Market Forecasts · NASDAQ:AMGN · Stock Analysis

Pfizer (PFE) Stock Outlook Before the December 1, 2025 Open: Price, Metsera Obesity Deal, Dividend Payout and Wall Street Forecasts

As U.S. markets prepare to reopen on Monday, December 1, 2025, Pfizer Inc. (NYSE: PFE) heads into the new week trading in a tight range but surrounded by a flurry of fresh analysis, institutional activity and strategic news from November

30 November 2025

Dividend Stocks · Financial Analysis · Investing · NYSE:PFE · Pharmaceuticals · Stock Market

Pfizer (PFE) Stock Today, November 26, 2025: Options Surge, Obesity Bet and Cancer Win Shape the Outlook

Pfizer Inc. (NYSE: PFE) heads into Wednesday, November 26, 2025 with its share price sitting just under the top of its recent trading range and a narrative that looks very different from the COVID‑era boom and bust. After climbing almost

26 November 2025

Financial Analysis · Health Trends · Investment Strategies · NYSE:PFE · Pharmaceuticals · Stock Market

PFE Stock Today (Nov. 25, 2025): Pfizer Rises on Metsera Obesity Deal, PADCEV Approval and Options Surge

Pfizer Inc. (NYSE: PFE) is back on many traders’ screens today. As of early afternoon on Tuesday, November 25, 2025, Pfizer shares are trading around $25.65, up roughly 1.7% on the session, after touching an intraday high near $25.96 and

25 November 2025

Health Business · Investment Analysis · NYSE:PFE · Pfizer News · Pharmaceutical Industry · Stock Market

VKTX Stock Today, November 25, 2025: Can Viking Therapeutics Keep Riding the Obesity Drug Wave?

Viking Therapeutics (NASDAQ: VKTX) heads into the Tuesday, November 25, 2025 session trading in the mid‑$30s, still digesting last week’s major milestone: the company has finished enrolling patients in its pivotal Phase 3 obesity trial VANQUISH‑1 ahead of schedule and

25 November 2025

Biotech · Investing · Obesity Drugs · Pharmaceuticals · Stock Market